ABSTRACT. Human carnitine palmitoyl transferase (CTP) deficiency results in two different clinical variants, one with "hepatic" and one with "muscular" symptoms. We studied CPT activity and long-chain fatty acid oxidation in fibroblast cell lines from four patients, two from each group. Overall CPT activity was deficient in patients' fibroblasts with the hepatic presentation, as previously demonstrated in patients' fibroblasts with the muscular presentation. The hepatic patients' fibroblasts displayed a CPTl deficiency which resulted in impaired long-chain fatty acid oxidation. In contrast, CPTl activity and palmitate oxidation were normal in muscular patients' fibroblasts. In these latter patients, the mutation presumably involved CPT2 activity. These data suggest that CPT deficiency is due to at least two different mutations, resulting in two distinct patterns of clinical and biochemical abnormalities. (Pediatr Res 24: 308-31 1, 1988) 
priately low ketogenesis. In this disorder, CPT deficient activity has been demonstrated in liver. However, the defect is probably not limited to the liver because this patient's fibroblasts also exhibited impaired long-chain fatty acid oxidation (1 3). In the "muscular" presentation, the defect has been demonstrated in all tissues studied, including muscle, liver, leukocytes, platelets, and fibroblasts (1 1, 14) . In all these studies, the methodology of CPT assays did not allow a clear discrimination between CPTl and CPT2 activities. Thus it was not possible to evaluate if the two different clinical presentations resulted from distinct enzymatic defects affecting CPT, and/or CPT2 activities.
We compared CPT activities and long-chain fatty acid oxidation in four patients' fibroblasts, two with "hepatic" and the other two with "muscular" presentations. Our results suggest that there are at least two varieties of CPT deficiency, each presenting distinct biochemical abnormalities in cultured fibroblasts. CASE 
REPORTS
Case I. The patient was fully reported in 198 1 (1 2). She was referred at 8 months of age for coma with seizures related to hypoglycemia after 16 h of fasting. She had minimal hepatomegaly without clinical muscular symptomatology or biochemical muscular abnormalities. A 19-h fasting test resulted in a marked hypoglycemia (1.8 mmol/liter) with deficient ketogenesis (<0.2 mmol/liter) reversible by the administration of medium-chain triglycerides. The hepatic histology showed an accumulation of triglycerides, whereas total liver carnitine was normal. Hepatic CPT activity (measured by an "isotope exchange" assay) was greatly reduced. CPT activity was not determined in other tissues but impaired oxidation of palmitate was demonstrated in cultured fibroblasts (13) . The child is now l l yr old and has no clinical or biologic muscular symptoms.
Case ZZ. The patient, a 1-yr-old boy, was referred for hypoglycemic coma. At the end of a 19-h fasting test, blood glucose fell to 1.3 mmol/liter. Blood ketones level was 0.3 mmol/liter, contrasting with blood free fatty acid concentration of 2.5 mmoll liter. Total and free blood carnitine were 55 and 45 pmol/liter. Urinary organic acid excretion displayed no abnormal pattern. A liver biopsy was not accepted by the parents. The child is now 10 yr old and no clinical or biologic symptom can be demonstrated.
Case ZII. The patient has been described previously (15) . At the age of 12 yr, the boy first experienced muscular cramps and rhabdomyolysis after prolonged physical exercise. Many subsequent episodes of rhabdomyolysis were all induced by prolonged effort, particularly when performed during a fasting test. At the age of 22 yr, an identical episode resulted in acute renal failure.
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An ischemic forearm exercise test performed several months after this attack resulted in a normal rise of plasma lactate. The total carnitine content of muscle was not decreased. The CPT activity was markedly deficient in muscle and fibroblasts using the isotope exchange method.
Case ZV. The patient has been described ( 14) and was clinically similar to case 111. The CPT defect was demonstrated in muscle and liver without noticeable clinical hepatic symptomatology. Fibroblasts failed to exhibit any CPT defect when tested with forward and isotope exchange assays (described in the case report) but expressed the CPT defect with an assay similar to assay B (Rimoldi M, unpublished data).
MATERIALS AND METHODS
Fibroblasts were cultured as previously described (13) (13) with modifications (16) .
CPT activity was assayed in the 150 x g supernatant of fibroblast homogenates in which mitochondrial integrity was preserved. The homogenization was performed in 150 mM KC1 50 mM tris, pH 7.4, by sonication (MSE sonicator; medium power; 14 pM peak to peak amplitude; 3 s; 4" C). Mitochondria1 integrity was assessed by assaying citrate synthase (EC 4.1.3.7) (17) in the supernatant after a 9000 X g centrifugation for 15 min. Usually less than 20% of the total citrate synthase activity was present in the supernatant.
The assay of CPTl activity only requires conditions preserving mitochondrial membrane integrity. CPTl activity is characterized by its total inhibition by malonyl CoA (4). We tested these conditions in assay A, similar to assay 2 of McGarry et al. (4) . This assay measured palmitoyl-L-(methy13H) carnitine production from L-(methy13H) carnitine and palmitoyl-CoA. The 550 pl incubation mixture contained 1 15 mM Tris pH 7.4; 4.5 mM reduced glutathione; 70 mM KC1; 110 pM palmitoyl CoA complexed with 1% fatty acid-free bovine serum albumin (wtlvol), and homogenate. After a 2.5-min preincubation with and without malonyl CoA, the reaction was initiated by the addition of 540 pM L-(methy13H) carnitine. The actual concentrations of malonyl CoA added in the preincubation mixture are indicated in figure 1 and Table 1 . The reaction was stopped as described by Solberg (18) . Km of CPT, for carnitine and palmitoyl CoA was determined on two different control fibroblasts homogenates. At 500 pM L-carnitine, Km for palmitoyl CoA was 28 and 23 pM. K, for carnitine was 38 and 35 pM when determined with 100 pM palmitoyl CoA.
The assay of CPTl activity is hampered by its localization on the inner face of mitochondrial membrane. CPT activity was measured after disruption of mitochondrial membranes with palmitoyl carnitine as a detergent (assays B and C). medium contained 115 mM Tris pH 7.4; 70 mM KC1; 8 mM mal. Conversely, in cell lines I11 and IV, long-chain fatty acid CoA; 4.5 mM reduced glutathione; and homogenate. After a 2.5-oxidation was not reduced, irrespective of the concentration of min preincubation, the reaction was initiated by the addition of palmitate used in the experiments and of the presence of L-2 mM palmitoyl-L-(methy13H) carnitine. The reaction was carnitine. The apparent Km for palmitate was 19.5 f 4.5 pM (n stopped with 0.6 M perchloric acid. After centrifugation, an = 4) for controls and 18.3 pM (n = 2) and 20.5 pM (n = 2) in aliquot of supernatant containing L-(methy13H) carnitine was cell lines I11 and IV, respectively. counted in scintillation medium. Assay C was performed as described (19) . It measured palmitoyl-L-(methy13H) carnitine DISCUSSION production from L-(methy13H) carnitine and palmitoyl CoA in the absence of albumin and in the presence of palmitoyl-D-CPT deficiency with a muscular presentation has been decarnitine in a volume of 500 p1 containing 40 p~ palmitoyl scribed in nearly 40 patients and has been recently reviewed (1 1). COA, 1 mM L-carnitine, and 1 mM palmitoyl-~-carnitine. The The clinical presentation is stereotyped. The patient is most often assays were linear with incubation time (3-8 min) and added an adolescent male and experiences acute episodes of rhabdoprotein when performed with 50-250 g protein in assays A and myolisis after prolonged exercise or occasionally after prolonged C and 50-120 g protein in assay B. Incubation time was 5 min. fasting. Spontaneous attacks are possible but muscle cramps are Protein was determined by the method of Lowry et al. (20) .
rare. Acute renal failure can occur during acute attacks. Serum COA, palmitoyl COA, palmitoyl-L-carnitine, octanoic acid, pal-and muscle carnitine levels are not usually decreased but lipid rnitic acid, succinic acid, and fatty acid-free bovine serum albu-accumulation is occasionally demonstrated in muscle biopsies. min were purchased from Sigma Chemical Co. (St. Louis, MO). CPT deficiency is not restricted to muscle but is also found in Palmitoyl-~-camitine was synthetized as described (2 1). L-Car-all other tissues (e.g. liver, leukocytes, platelets, fibroblasts) studnitine was a gift from Sigma-Tau France. Reduced glutathione ied. The hepatic consequences of this defect are minor and fasting was purchased from Boehringer. Ketone body production 14CIpalmitic acid, [1,4-14C] succinic acid, and methyl 3H) Car-was delayed during fasting in the few patients thus studied. TO nitine were purchased from Amersham (UK). Palmitoyl-L-our knowledge, patient I represents the only reported case (12) (methyl 3H) carnitine was synthetized as described (22) .
with hepatic presentation of CPT deficiency. Symptomatic hypoketotic hypoglycemia was the main clinical problem. In con-RESULTS trast to patients with long-chain fatty acid oxidation defects, such as systemic carnitine deficiency (23) or long-chain acyl CoA CPTl activity was identified by its suppressibility by malonyl dehydrogenase deficiency (24) , heart and skeletal muscle were CoA (4). In control fibroblasts (Fig. l) , CPT activity measured not affected in patients I and 11. Although direct assays in tissues by assay A was inhibited by malonyl CoA in a dose-dependent other than liver were not performed, the defect was probably not fashion. The maximum effect (90% inhibition) was obtained restricted to liver, because this patient's fibroblasts exhibited a with 50pM malonyl CoA. The Iso was approximately 1.2 pM, severe impairment of long-chain fatty acid oxidation (12) . similar to values obtained in rat and human fetal liver (6) . In
These distinct clinical presentations of CPT deficiency could cell lines I and I1 (hepatic presentation), CPT activity measured result from distinct mutations affecting either CPTl or CPT2 by assay A was impaired (residual activities 15 and 25% of activities. The review of the literature failed to answer this control, respectively) ( Table 1) . By contrast, CPT activity meas-question, as the assays used did not discriminate between CPTl ured by this assay was normal in cell lines I11 and IV (muscular and CPT2 activities. In intact mitochondria, CPT is known to presentation). Inhibition by 50 pM malonyl CoA, V,,,, and Km exist as an overt (CPTI) and a latent (CPT2) form. The latter is for palmitoyl CoA and L-carnitine were similar to controls in exposed by agents or procedures that disrupt membrane. CPT cell lines I11 and IV (data not shown). In assays B and C, activity of fibroblasts was measured by three assays (A, B, C), in performed in the presence of detergent, cell lines I11 and IV homogenates in which mitochondrial integrity was preserved (see exhibited an impaired CPT activity (residual activity 25 to 30% Materials and Methods). CPT activity, as measured as palmitoyl of control). By contrast, in cell lines I and 11, CPT activity carnitine synthesis in nondetergent conditions (assay A), was measured by these assays was normal. suppressed (>go%) by 50 pM malonyl CoA, a specific inhibitor The consequences of impaired CPT activity on the oxidation of CPTl (4), suggesting this assay specifically measured CPTl of fatty acids were studied in intact fibroblasts. In cell lines I and activity. The assay of CPT2 required treatments that disrupted 11, the oxidation of palmitate was dramatically decreased, mitochondrial membranes. This requirement was fulfilled in whereas the oxidation of succinate and octanoate (which enters assays B (used in most published clinical cases) and C, performed the mitochondria by a CPT-independent mechanism) were nor-in detergent conditions (19) . Carnitine release was measured in Table 2 assay B and palmitoyl carnitine synthesis was measured in assay C. Although these assays are supposed to investigate total (I + 2) CPT activity, D-and L-palmitoyl carnitine used as detergents in assays B and C also inhibited a fraction of CPT activity, presumably CPT, activity (7) (8) (9) . As a consequence, assays B and C likely measure CPTl activity only. We studied CPT activities in four patients' fibroblasts, two of them presenting the hepatic form and the other two the muscular form. Patients' cell lines with hepatic presentation exhibited a defective CPT, activity. Conversely, in these cells, CPT activity was not impaired when measured in detergent conditions, suggesting an intact CPT2 activity. In patients' cell lines with muscular presentation, assay A failed to evidence a decreased activity, irrespective of the concentration of albumin (0.1 to I %) and palmitoyl CoA (10 to 300 pM) used in the assay (data not shown), contrasting with Zierg and Engel's results (25) . They demonstrated an impaired CPT activity in muscle mitochondria from muscular presentation patients in an assay similar to assay A performed with 0.1 % albumin and 200 pM palmitoyl CoA. This discrepancy between our data and those of Zierg and Engel (25) might be due to differences in the cellular material used (intact fibroblast mitochondria versus disrupted muscle mitochondria).
However, CPT activity of "muscular" cell lines was markedly reduced when measured in detergent conditions, in agreement with earlier data (1 5, 25) ; indeed, muscular CPT deficiency was usually shown under such conditions. Thus the impaired CPT activity measured by assays B and C could be explained by a defect of CPT2 activity. These data show that the two clinical forms of CPT deficiency are caused by different mutations. As we only studied two cases of each clinical presentation of CPT deficiency, investigations of other patients must be performed to establish a firm correlation between clinical and biochemical data.
The metabolic consequences of CPT deficiency also differentiated muscular and hepatic cell lines; only the latter exhibited reduced long-chain fatty acid oxidation. These data might be compared with clinical consequences of CPT defects in hepatic and muscular forms. It was striking that, despite liver CPT deficiency in both forms (4), hypoketotic hypoglycemia only occurred in the hepatic form. These data suggest that CPTl activity determines overall fatty acid oxidation in fibroblasts and liver as well. The lack of muscular symptoms in the hepatic presentation is puzzling. Along this line, we hope to perform muscle biopsies in our two hepatic patients in order to measure muscular CPT activities.
